Short answer
ARDELYX, INC. (ARDX) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results announced for quarter ended March 31, 2026.
ARDELYX, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results announced for quarter ended March 31, 2026
- Full results and management commentary furnished in Exhibit 99.1
- Earnings disclosure provides the market’s primary update on quarterly operating performance
Item 7.01 · Regulation FD Disclosure
- Earnings presentation for quarter ended March 31, 2026 furnished as Exhibit 99.2
- Conference call scheduled for April 30, 2026, providing management commentary on quarterly results
- Investors should review Exhibit 99.2 for operating metrics and financial guidance disclosed with the presentation
Item EX-99.1 · Exhibit EX-99.1
- Q1 product revenue $93.4M, up 38% year over year, led by IBSRELA revenue of $70.1M, up 58%
- 2026 guidance reaffirmed: IBSRELA revenue $410M-$430M and XPHOZAH revenue $110M-$120M
- Net loss narrowed to $37.6M, or $0.15 per share, from $41.1M, or $0.17 per share
- Cash, equivalents and investments declined to $238.1M from $264.7M at December 31, 2025
- ACCEL Phase 3 enrollment expected by end-2026, with topline data targeted for the second half of 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARDELYX, INC. 8-K filings
Get the next ARDX 8-K as it lands
Follow ARDX for push alerts, or ask the research agent what this filing means.